Keywords: cost, effectiveness, sandimmun, neoral, pharmacoeconomic, analysis, renal

Cost Effectiveness Of Sandimmun Neoral

Article | 31 October 1994

A pharmacoeconomic analysis of 86 renal transplant patients has shown that Sandoz' new formulation of ciclosporin, Sandimmun Neoral, can cut medical ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Sandoz

Go to company listing

Related Drugs

Cyclosporine

Neoral

Go to drug listing